Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease.
Mark W TenfordeTimothée Boyer-ChammardCharles MuthogaLeabaneng TaweThandi MiltonIkanyeng RulaganyangKwana LechiileIvy RukashaTshepo B LeemeNelesh P Govender MMedJulia NgidiMadisa MineSíle F MolloyThomas S HarrisonOlivier LortholaryJoseph N JarvisPublished in: Journal of clinical microbiology (2020)
High cryptococcal antigen (CrAg) titers in blood are associated with subclinical meningitis and mortality in CrAg-positive individuals with advanced HIV disease (AHD). We evaluated a novel semiquantitative lateral flow assay (LFA), CryptoPS, that may be able to identify individuals with high CrAg titers in a cohort of AHD patients undergoing CrAg screening. In a prospective cohort of patients with AHD (CD4 cell count, ≤200/μl) receiving CD4 count testing, whole blood was tested for CrAg by CryptoPS and the IMMY LFA; the two assays were conducted by two different operators, each blind to the results of the other assay. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of CryptoPS were assessed against the IMMY LFA as a reference. CryptoPS low-titer (T1 band) and high-titer (T2 band) results were compared with IMMY LFA titers obtained through serial dilution. A total of 916 specimens were tested. The sensitivity of the CryptoPS assay was 61.0% (25/41) (95% confidence interval [95% CI], 44.5 to 75.8%), its specificity was 96.6% (845/875) (95% CI, 95.1 to 97.7%), its PPV was 45.5% (95% CI, 32.0 to 59.4%), and its NPV was 98.1% (95% CI, 97.0 to 98.9%). All (16/16) CryptoPS false-negative results were obtained for samples with IMMY titers of ≤1:160. Of 29 patients (30 specimens) who tested positive by CryptoPS but negative by the IMMY LFA, none developed cryptococcal meningitis over 3 months of follow-up without fluconazole. Median CrAg titers were 1:20 (interquartile range [IQR], 0 to 1:160) in CryptoPS T1-positive samples and 1:2,560 (IQR, 1:1,280 to 1:10,240) in T2-positive samples. We conclude that the diagnostic accuracy of the CryptoPS assay was suboptimal in the context of CrAg screening, with poor sensitivity at low CrAg titers. However, the CryptoPS assay reliably detected individuals with high titers, which are associated with poor outcomes.
Keyphrases
- high throughput
- patients undergoing
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv infected
- hepatitis c virus
- end stage renal disease
- hiv testing
- single cell
- cardiovascular disease
- newly diagnosed
- hiv aids
- cardiovascular events
- cell therapy
- risk factors
- men who have sex with men
- stem cells
- coronary artery disease
- type diabetes
- peripheral blood
- prognostic factors
- high resolution
- peritoneal dialysis
- adipose tissue
- patient reported outcomes
- tandem mass spectrometry